CN1738619B - 给予体外部分成熟的树突细胞治疗肿瘤的制药用途 - Google Patents

给予体外部分成熟的树突细胞治疗肿瘤的制药用途 Download PDF

Info

Publication number
CN1738619B
CN1738619B CN2003801089756A CN200380108975A CN1738619B CN 1738619 B CN1738619 B CN 1738619B CN 2003801089756 A CN2003801089756 A CN 2003801089756A CN 200380108975 A CN200380108975 A CN 200380108975A CN 1738619 B CN1738619 B CN 1738619B
Authority
CN
China
Prior art keywords
tumor
administered
cells
dendritic cell
bcg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2003801089756A
Other languages
English (en)
Chinese (zh)
Other versions
CN1738619A (zh
Inventor
M·L·博希
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Northwest Biotherapeutics LLC
Original Assignee
Northwest Biotherapeutics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Northwest Biotherapeutics LLC filed Critical Northwest Biotherapeutics LLC
Priority to CN201210027703.4A priority Critical patent/CN102600461B/zh
Publication of CN1738619A publication Critical patent/CN1738619A/zh
Application granted granted Critical
Publication of CN1738619B publication Critical patent/CN1738619B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/50—Colon
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/70—Undefined extracts
    • C12N2500/72—Undefined extracts from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/05—Adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN2003801089756A 2002-12-06 2003-12-05 给予体外部分成熟的树突细胞治疗肿瘤的制药用途 Expired - Fee Related CN1738619B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201210027703.4A CN102600461B (zh) 2002-12-06 2003-12-05 给予体外部分成熟的树突细胞治疗肿瘤

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US43126702P 2002-12-06 2002-12-06
US60/431,267 2002-12-06
US60/431267 2002-12-06
PCT/US2003/038672 WO2004053072A2 (en) 2002-12-06 2003-12-05 Administration of dendritic cells partially matured in vitro for the treatment of tumors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201210027703.4A Division CN102600461B (zh) 2002-12-06 2003-12-05 给予体外部分成熟的树突细胞治疗肿瘤

Publications (2)

Publication Number Publication Date
CN1738619A CN1738619A (zh) 2006-02-22
CN1738619B true CN1738619B (zh) 2012-04-18

Family

ID=32507696

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2003801089756A Expired - Fee Related CN1738619B (zh) 2002-12-06 2003-12-05 给予体外部分成熟的树突细胞治疗肿瘤的制药用途
CN201210027703.4A Expired - Fee Related CN102600461B (zh) 2002-12-06 2003-12-05 给予体外部分成熟的树突细胞治疗肿瘤

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201210027703.4A Expired - Fee Related CN102600461B (zh) 2002-12-06 2003-12-05 给予体外部分成熟的树突细胞治疗肿瘤

Country Status (18)

Country Link
US (2) US20060057120A1 (enExample)
EP (2) EP2260861A1 (enExample)
JP (2) JP4859169B2 (enExample)
KR (1) KR101144196B1 (enExample)
CN (2) CN1738619B (enExample)
AT (1) ATE486125T1 (enExample)
AU (2) AU2003293411B2 (enExample)
BR (1) BRPI0317064B8 (enExample)
CA (1) CA2509058A1 (enExample)
DE (1) DE60334725D1 (enExample)
DK (1) DK1567155T3 (enExample)
ES (1) ES2354944T3 (enExample)
IL (1) IL169002A (enExample)
MX (1) MXPA05006042A (enExample)
PL (1) PL377209A1 (enExample)
PT (1) PT1567155E (enExample)
RU (1) RU2348418C2 (enExample)
WO (1) WO2004053072A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102600461A (zh) * 2002-12-06 2012-07-25 西北生物治疗药物公司 给予体外部分成熟的树突细胞治疗肿瘤

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070134273A1 (en) * 2004-02-10 2007-06-14 Francois Romagne Composition and method for the treatment of carcinoma
US20060216269A1 (en) * 2004-09-17 2006-09-28 Kenichiro Hasumi Dendritic cell tumor injection (DCTI) therapy
US8076132B2 (en) 2004-09-17 2011-12-13 Hasumi International Research Foundation Dendritic cell tumor injection (DCTI) therapy
WO2006095330A2 (en) * 2005-03-10 2006-09-14 Yeda Research And Development Co. Ltd. Methods and immunogenic cell preparations for treating antigen-associated diseases
WO2007001200A1 (en) * 2005-06-23 2007-01-04 Obschestvo S Ogranichennoi Otvetsvennostyu 'rusgen' Mature dendritic cells loaded with tumor polylysates and antitumoral vaccine base thereon
AR060424A1 (es) * 2007-04-11 2008-06-18 Consejo Nac Invest Cient Tec Lineas celulares , composiciones para el tratamiento de melanomas que las comprenden procedimientos para preparar las composiciones y metodos de tratamiento
WO2008133595A1 (en) * 2007-04-26 2008-11-06 Newbiomed Pika Pte Ltd Compositions and methods for stimulating an immune response in-vivo and in-vitro
WO2008151389A1 (en) * 2007-06-15 2008-12-18 Macfarlane Burnet Institute For Medical Research And Public Health Limited Chemically modified macromolecules
EP2072617A1 (en) * 2007-12-12 2009-06-24 Trimed Biotech GmbH Method for producing dendritic cells
RU2361598C1 (ru) * 2008-02-18 2009-07-20 Тихоокеанский Институт Биоорганической Химии Дальневосточного Отделения Российской Академии Наук (Тибох Дво Ран) Средство, индуцирующее созревание дендритных клеток
CA3123228A1 (en) * 2008-03-27 2009-10-01 Asterias Biotherapeutics, Inc. Differentiation of primate pluripotent stem cells to hematopoietic lineage cells
KR101788885B1 (ko) * 2009-07-09 2017-10-20 타이제닉스, 에스.에이.유. 세포 요법에 사용하기 위한 방법 및 조성물
ES2581277T3 (es) * 2010-02-10 2016-09-05 Immunicum Ab Composición mejorada para inhibir la proliferación de células tumorales
CA2793458A1 (en) * 2010-03-15 2011-09-22 The Trustees Of The University Of Pennsylvania System and method of preparing and storing activated mature dendritic cells
RU2530523C2 (ru) * 2012-03-29 2014-10-10 Олег Борисович Егоров Способ противоопухолевой иммунотерапии
SG11201510552WA (en) 2012-06-27 2016-01-28 Hasumi Internat Res Foundation Therapy and method for intratumorally introducing cytotoxic t lymphocyte and/or nkt cell with anti-tnf and/or anti-il-10
GB201300049D0 (en) * 2013-01-03 2013-02-20 Transimmune Ag Method for obtaining immuno-stimulatory dendritic cells
KR20160093012A (ko) 2013-11-05 2016-08-05 코그네이트 바이오서비시즈, 인코포레이티드 암 치료를 위한 체크포인트 억제제 및 치료제의 배합물
GB201413665D0 (en) 2014-07-03 2014-09-17 Transimmune Ag And Yale University Method for obtaining globally activated monocytes
CN114774356A (zh) 2015-06-30 2022-07-22 西北生物治疗药物公司 诱发改善的或增加的抗肿瘤免疫应答的经最佳活化的树突细胞
WO2017048875A1 (en) * 2015-09-15 2017-03-23 Northwest Biotherapeutics, Inc Methods relating to activated dendritic cell compositions and immunotherapeutic treatments for subjects with advanced cancers
KR101749165B1 (ko) * 2016-06-07 2017-06-23 충남대학교산학협력단 Rv2299c 또는 Rv2299c와 ESAT-6 융합한 단백질을 포함하는 수지상 세포의 성숙화 촉진용 조성물
WO2018160666A1 (en) * 2017-02-28 2018-09-07 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Short-term activated dc1s and methods for their production and use
GB201711379D0 (en) * 2017-07-14 2017-08-30 Univ Cape Town Maturation of dendritic cells
CN109957548B (zh) * 2017-12-26 2022-03-18 上海尚泰生物技术有限公司 一种基因修饰的树突状细胞疫苗
GB2624871A (en) * 2022-11-29 2024-06-05 Alv B As Process for preparing a population of dendritic cells and immunotherapy using the same
EP4520334A1 (en) 2023-09-07 2025-03-12 Mnemo Therapeutics Methods and compositions for improving immune response
WO2025052001A1 (en) 2023-09-07 2025-03-13 Mnemo Therapeutics Methods and compositions for improving immune response

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5A (en) * 1836-08-10 Thomas Blanchard Machine for mortising solid wooden shells of ships' tackle-blocks
DK0633929T3 (da) 1992-04-01 2004-06-28 Univ Rockefeller Fremgangsmåde til in vitro proliferation af dendritcelleforstadier og deres anvendelse til at producere immunogener
US5788963A (en) * 1995-07-31 1998-08-04 Pacific Northwest Cancer Foundation Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy
ATE428769T1 (de) * 1997-10-27 2009-05-15 Univ Rockefeller Methode und zusammensetzung zur herstellung von reifen dendritischen zellen
US6797488B1 (en) * 1997-12-08 2004-09-28 Beth Israel Deaconess Medical Center Methods of producing anti-angiogenic proteins
AU6144499A (en) * 1998-09-15 2000-04-03 University Of Pittsburgh In situ injection of antigen-presenting cells with genetically enhanced cytokineexpression
CN1321189A (zh) * 1998-10-02 2001-11-07 三菱化学株式会社 细胞性免疫的诱导方法以及被诱导了细胞免疫的细胞
US6649158B1 (en) * 1998-10-15 2003-11-18 Canji, Inc. Methods and compositions to induce antitumor response
US6558951B1 (en) * 1999-02-11 2003-05-06 3M Innovative Properties Company Maturation of dendritic cells with immune response modifying compounds
JP2002541195A (ja) * 1999-04-14 2002-12-03 アメリカ合衆国 移植片に対する免疫寛容を誘導するための、免疫毒素および樹状細胞の成熟を阻害する作用剤を含有する組成物
WO2001048154A1 (en) * 1999-12-28 2001-07-05 Toyoshima, Kumao Maturation-promoting agent for immature dendritic cells
JP4841794B2 (ja) * 2000-05-12 2011-12-21 ノースウエスト バイオセラピューティクス，インコーポレイティド ヒト樹状細胞による外因性抗原のクラスｉ提示を増加させる方法
JP2002069001A (ja) * 2000-08-29 2002-03-08 Asahi Kasei Corp 樹状細胞を主成分とする細胞ワクチン
AU2002224851A1 (en) * 2000-11-14 2002-05-27 Universite Libre De Bruxelles Generation and use of dendritic cells
US20020094545A1 (en) 2000-11-30 2002-07-18 Harris Paul E. Growth of human dendritic cells for cancer immunotherapy in closed system using microcarrier beads
WO2003010292A2 (en) * 2001-07-25 2003-02-06 Northwest Biotherapeutics, Inc. Methods and apparatus for enrichment and culture of monocytic dendritic cell precursors
EP2322603B1 (en) * 2001-09-06 2019-10-16 NorthWest Biotherapeutics, Inc. Compositions and methods for priming monocytic dendritic cells and T cells for Th1 response
WO2004053072A2 (en) * 2002-12-06 2004-06-24 Northwest Biotherapeutics, Inc. Administration of dendritic cells partially matured in vitro for the treatment of tumors
DK1604016T3 (da) * 2003-02-27 2009-05-18 Northwest Biotherapeutics Inc In vitro-fremgangsmåde til differentiering af monocytiske dendritiske precursorceller i umodne dendritiske celler

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
KADOWAKI N. ET AL.Distinct CpG DNA and polyinosinic-polycytidilic acid doublestranded RNA, resspectively stimulate CD 11c- type 2dendritic cell precursors and CD 11+ dendritic cells toproduce typeI IFN.THE JOURNAL OF IMMUNOLOGY166.2001,2291- 2295. *
KADOWAKIN.ETAL.DistinctCpGDNAandpolyinosinic-polycytidilicaciddoublestrandedRNA resspectively stimulate CD 11c- type 2dendritic cell precursors and CD 11+ dendritic cells toproduce typeI IFN.THE JOURNAL OF IMMUNOLOGY166.2001
NESTLE F.O.Dendritic cell vaccination for cancer therapy.Oncogene19.2000,(19),6673-6679页.
NESTLE F.O.Dendritic cell vaccination for cancer therapy.Oncogene19.2000,196673-6679页.
NESTLE F.O.Dendritic cell vaccination for cancer therapy.Oncogene19.2000,(19),6673-6679页. *
NESTLE F.O.Dendritic cell vaccination for cancer therapy.Oncogene19.2000,196673-6679页. *
TSUJI S. ET AL.Maturation of human dendritic cells by cell wall skeleton ofMycobacterium bovis BacillusCalmette-Guerin: involvement of toll like receptors＇.INFECTION AND IMMUNITY68.2000,6883 - 6890页.
TSUJI S. ET AL.Maturation of human dendritic cells by cell wall skeleton ofMycobacterium bovis BacillusCalmette-Guerin: involvement of toll like receptors＇.INFECTION AND IMMUNITY68.2000,6883- 6890页. *
卞建民.树突细胞用于肿瘤特异性免疫治疗的研究进展.国外医学外科学分册 5.1998,(5),264页.
卞建民.树突细胞用于肿瘤特异性免疫治疗的研究进展.国外医学外科学分册 5.1998,(5),264页. *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102600461A (zh) * 2002-12-06 2012-07-25 西北生物治疗药物公司 给予体外部分成熟的树突细胞治疗肿瘤
CN102600461B (zh) * 2002-12-06 2017-07-14 西北生物治疗药物公司 给予体外部分成熟的树突细胞治疗肿瘤

Also Published As

Publication number Publication date
CN102600461B (zh) 2017-07-14
KR20050084189A (ko) 2005-08-26
WO2004053072A3 (en) 2005-06-16
KR101144196B1 (ko) 2012-05-21
ES2354944T3 (es) 2011-03-21
DK1567155T3 (da) 2011-02-14
MXPA05006042A (es) 2005-09-21
RU2348418C2 (ru) 2009-03-10
BR0317064A (pt) 2005-10-25
WO2004053072A2 (en) 2004-06-24
JP4859169B2 (ja) 2012-01-25
DE60334725D1 (de) 2010-12-09
JP5707284B2 (ja) 2015-04-30
US20060057120A1 (en) 2006-03-16
EP2260861A1 (en) 2010-12-15
BRPI0317064B8 (pt) 2021-05-25
AU2003293411A1 (en) 2004-06-30
US20120251561A1 (en) 2012-10-04
EP1567155A2 (en) 2005-08-31
PT1567155E (pt) 2011-01-28
PL377209A1 (pl) 2006-01-23
RU2005121256A (ru) 2006-02-10
CA2509058A1 (en) 2004-06-24
AU2011200352A1 (en) 2011-02-17
AU2003293411B2 (en) 2010-10-28
HK1082180A1 (en) 2006-06-02
IL169002A (en) 2015-01-29
BRPI0317064B1 (pt) 2020-11-03
JP2006510667A (ja) 2006-03-30
CN1738619A (zh) 2006-02-22
ATE486125T1 (de) 2010-11-15
CN102600461A (zh) 2012-07-25
JP2011246493A (ja) 2011-12-08
EP1567155B1 (en) 2010-10-27
EP1567155A4 (en) 2006-12-13
AU2011200352B2 (en) 2013-06-27

Similar Documents

Publication Publication Date Title
CN1738619B (zh) 给予体外部分成熟的树突细胞治疗肿瘤的制药用途
JP2006510667A5 (enExample)
US20220145246A1 (en) Optimally activated dendritic cells that induce an improved or increased anti-tumor immune response
AU2018260971B2 (en) Administration of dendritic cells partially matured in vitro for the treatment of tumors
AU2013234394B2 (en) Administration of dendritic cells partially matured in vitro for the treatment of tumors
HK40077476A (en) Optimally activated dendritic cells that induce an improved or increased anti-tumor immune response
HK1151249A (en) Administration of dendritic cells partially matured in vitro for the treatment of tumors
HK1082180B (en) Administration of dendritic cells partially matured in vitro for the treatment of tumors

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20120418

Termination date: 20211205